About CytomX Therapeutics, Inc. - Common Stock (CTMX)
CytomX Therapeutics is a biotechnology company focused on developing innovative cancer therapies through its proprietary Probody™ therapeutic technology. This platform is designed to selectively activate antibody-based treatments in the tumor microenvironment, helping to enhance the efficacy and reduce potential side effects of cancer therapies. CytomX is engaged in creating a pipeline of product candidates aiming to address various types of cancer, leveraging its expertise in protein engineering and immuno-oncology to advance treatment options and improve patient outcomes. The company collaborates with pharmaceutical partners to accelerate the development of its therapeutic candidates, with the goal of bringing novel, targeted therapies to market. Read More
NetworkNewsWire Editorial Coverage : Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades. By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX) , Crispr Therapeutics AG (NASDAQ: CRSP) and…
CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
